Medical/Pharmaceuticals
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy
SHANGHAI, Aug. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB ...
2023-08-21 08:20
3820
Sisram Medical to Report H1 2023 Financial Results on August 23 and Hold a Conference Call on August 24
H1 2023 conference call to be held on August 24, at 8:00 a.m. Eastern Time HONG KONG, Aug. 20, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the " Group"), a global consumer wellness group featuring a first-of-it...
2023-08-20 10:14
4913
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling
REYKJAVIK, Iceland and BERLIN, Aug. 18, 2023 /PRNewswire/ -- Reykjavik-based drug discovery company, 3Z, andGermany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the ...
2023-08-18 22:45
3522
QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation
JINAN, China, Aug. 18, 2023 /PRNewswire/ -- August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical's iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at th...
2023-08-18 09:50
3092
Everest Medicines' Partner Calliditas Therapeutics Announces Full Results From NefIgArd Phase 3 Trial published in The Lancet
SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced the publication inThe Lancet of the full data from the NeflgArd Phase 3 trial with Nefecon® in...
2023-08-18 08:41
4283
BoomerangFX expands into Australian Market Driven by Growing Demand for Aesthetic Medicine Services in Asia Pacific
Responding to Growing Customer Demand – Cloud-Based Clinic Software, Digital Marketing & eLearning Provider Makes Significant Advances in the Australian Market TORONTO and MIAMI, Aug. 17, 2023 /PRNewswire/ -- BoomerangFX, a global provider of Software as a Service (SaaS), specializing in compreh...
2023-08-18 00:01
2040
Novo Holdings participates in $290m strategic financing of Sangon Biotech
COPENHAGEN, Denmark, Aug. 17, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced it has participated in a $290 million (USD) strategic financing round of Sangon Biotech. Sangon is a leading provider of life science tools and services, enabling scient...
2023-08-17 09:44
3595
TraceLink Collaborates with GS1 US to Author GS1 US Addendum Guidance and XML Examples for GS1 US DSCSA Implementation Guideline R1.3 to Support EPCIS Data Exchange
Publication of the GS1 standard guidelines and technical examples provide a strong foundation to help companies accelerate their network connectivity and EPCIS-based sTI/TS data exchange to meet forthcomingNovember 2023 DSCSA deadlines. BOSTON, Aug. 17, 2023 /PRNewswire/ -- TraceLink Inc., the l...
2023-08-17 09:35
2214
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-08-17 08:00
5033
Oncoclínicas Group generated record earnings in the second quarter of 2023, R$309 million and a net profit of R$35 million
Efficient management of working capital explains a large part of the cash flow performance. Net income grew 51% (31% organically) while the Ebitda Ex-LTIP (excluding only the non-cash impact of the long-term incentive plan) reached R$268 million, 109% greater than the same period last year SÃO PA...
2023-08-16 19:00
3311
Record number of participants expected at Medlab Asia & Asia Health 2023
BANGKOK, Aug. 16, 2023 /PRNewswire/ -- Medlab Asia & Asia Health 2023, organised by Informa Markets and IMPACT Exhibition Management in collaboration with the Central Sterilizing Services Association, has officially opened to showcase the latest techniques and innovations in the healthcare and lab...
2023-08-16 16:08
3401
Nippon Express (Ireland) Opens New Warehouse in Dublin, Beginning Operations July 1
TOKYO, Aug. 16, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a new warehouse, "Contract Logistics Center," inDublin city, beginning its operations onJuly 1. Logo: https://kyodonewsprwire.jp/img/2023...
2023-08-16 14:00
3278
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines
'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines... The first case of overseas launch SEOUL, South Korea, Aug. 16, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that 'Fuxuprazan' is officially launched i...
2023-08-16 13:00
4083
MGI Unveils Latest MGISP-NEX and MGIFLP-L50 Automation Systems at Medlab Asia & Asia Health 2023
BANGKOK, Thailand, Aug. 16, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, today announced the global launch of MGISP-NEX and MGIFLP-L50 automation platforms at Medlab Asia & Asia Health 2023, taking place from 16-18 August at IMPACT E...
2023-08-16 11:00
3367
Charmacy Pharmaceutical Has Obtained the Provincial Capital Support
Future Expected Rapidly Growth HONG KONG, Aug. 16, 2023 /PRNewswire/ -- Charmacy Pharmaceutical Co., LTD. ( Charmacy Pharmaceutical, stock code: 2289.HK), as a leading private pharmaceutical distributor inSouth China, has been actively seeking strategic cooperation and resource complementary fro...
2023-08-16 09:00
5108
MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients
GENEVA, Aug. 16, 2023 /PRNewswire/ -- MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-...
2023-08-16 08:00
3281
Transcenta to Present Three Study Results at ESMO 2023
SUZHOU, China, Aug. 16, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to ...
2023-08-16 08:00
3218
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biop...
2023-08-16 05:00
3534
CStone Pharmaceuticals Reports 2023 Interim Results and Updates
* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmaceutical products revenue was RMB 246.9 million, representing a growth rate of 53% compared to the same period last year. Commercial gross profit margin improved from 47% to 59%. * Healthy fin...
2023-08-15 22:33
5962
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)
SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase in...
2023-08-15 20:19
4710
Week's Top Stories
Most Reposted
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 295 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 284 media titles]
2026-10-15 10:00SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 282 media titles]
2026-10-15 12:59
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 273 media titles]
2026-10-21 15:00
Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
29890
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
19733